Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Systems Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1424207

Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout

Provisionally accepted
Shuaiwei Song Shuaiwei Song Xintian Cai Xintian Cai Junli Hu Junli Hu *Qing Zhu Qing Zhu *Di Shen Di Shen Huimin Ma Huimin Ma *Yingying Zhang Yingying Zhang *Rui Ma Rui Ma *Pan Zhou Pan Zhou *Wenbo Yang Wenbo Yang *Jing Hong Jing Hong *Delian Zhang Delian Zhang *Nanfang Li Nanfang Li *
  • People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China

The final, formatted version of the article will be published soon.

    Background: Prior research has highlighted the association between uric acid (UA) and the activation of the renin-angiotensin-aldosterone system (RAAS). However, the specific relationship between aldosterone, the RAAS's end product, and UA-related diseases remains poorly understood. This study aims to clarify the impact of aldosterone on the development and progression of hyperuricemia and gout in hypertensive patients.Methods: Our study involved 34534 hypertensive participants, assessing plasma aldosterone concentration (PAC)'s role in UA-related diseases, mainly hyperuricemia and gout. We applied multiple logistic regression to investigate the impact of PAC and used restricted cubic splines (RCS) for examining the dose-response relationship between PAC and these diseases. To gain deeper insights, we conducted threshold analyses, further clarifying the nature of this relationship. Finally, we undertook subgroup analyses to evaluate PAC's effects across diverse conditions and among different subgroups.Results: Multivariate logistic regression analysis revealed a significant correlation between the occurrence of hyperuricemia and gout and the elevation of PAC levels.Compared to the first quartile (Q1) group, groups Q2, Q3, and Q4 all exhibited a significantly increased risk of occurrence. Moreover, the conducted RCS analysis demonstrated a significant nonlinear dose-response relationship, especially when PAC was greater than 14 ng/dL, with a further increased risk of hyperuricemia and gout.Finally, comprehensive subgroup analyses consistently reinforced these findings.This study demonstrates a close association between elevated PAC levels and the development of UA-related diseases, namely hyperuricemia and gout, in hypertensive patients. Further prospective studies are warranted to confirm and validate this relationship.

    Keywords: Plasma aldosterone concentration, Hypertension, Uric Acid, Hyperuricemia, Gout

    Received: 27 Apr 2024; Accepted: 03 Jul 2024.

    Copyright: © 2024 Song, Cai, Hu, Zhu, Shen, Ma, Zhang, Ma, Zhou, Yang, Hong, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Junli Hu, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Qing Zhu, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Huimin Ma, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Yingying Zhang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Rui Ma, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Pan Zhou, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Wenbo Yang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Jing Hong, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Delian Zhang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Nanfang Li, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.